HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $165,185,662 | +5.9% | 4,324,232 | +0.0% | 3.73% | +12.3% |
| Q2 2023 | $155,949,078 | -4.9% | 4,323,512 | +0.7% | 3.32% | -5.0% |
| Q1 2023 | $164,033,077 | -27.6% | 4,295,184 | +7.8% | 3.50% | -31.7% |
| Q4 2022 | $226,679,017 | +29.7% | 3,983,814 | -9.8% | 5.12% | +14.5% |
| Q3 2022 | $174,724,000 | -3.4% | 4,418,928 | +7.5% | 4.47% | -8.8% |
| Q2 2022 | $180,848,000 | +12.2% | 4,110,174 | +1.7% | 4.90% | +19.3% |
| Q1 2022 | $161,231,000 | -1.4% | 4,042,906 | -0.5% | 4.10% | +4.0% |
| Q4 2021 | $163,445,000 | +17.2% | 4,064,779 | +18.6% | 3.95% | +6.9% |
| Q3 2021 | $139,430,000 | -3.3% | 3,427,476 | +7.9% | 3.69% | -8.5% |
| Q2 2021 | $144,241,000 | +18.5% | 3,176,404 | +8.7% | 4.04% | +15.3% |
| Q1 2021 | $121,771,000 | -13.6% | 2,920,860 | -11.5% | 3.50% | -24.1% |
| Q4 2020 | $140,943,000 | +58.7% | 3,300,001 | -2.4% | 4.61% | +21.2% |
| Q3 2020 | $88,824,000 | -2.6% | 3,379,927 | -0.6% | 3.81% | -7.8% |
| Q2 2020 | $91,193,000 | +49.4% | 3,401,470 | +0.2% | 4.13% | +18.8% |
| Q1 2020 | $61,041,000 | -1.5% | 3,393,057 | -2.9% | 3.48% | +42.5% |
| Q4 2019 | $61,982,000 | +46.8% | 3,495,892 | +28.4% | 2.44% | +31.7% |
| Q3 2019 | $42,216,000 | -10.0% | 2,721,858 | -0.3% | 1.85% | -11.9% |
| Q2 2019 | $46,884,000 | +3.0% | 2,729,005 | -3.5% | 2.10% | -2.1% |
| Q1 2019 | $45,508,000 | +9.8% | 2,826,601 | -0.3% | 2.15% | -4.3% |
| Q4 2018 | $41,458,000 | -4.4% | 2,833,759 | +18.7% | 2.24% | +16.3% |
| Q3 2018 | $43,378,000 | +8.2% | 2,387,350 | +0.5% | 1.93% | +1.6% |
| Q2 2018 | $40,081,000 | -13.0% | 2,375,876 | +1.0% | 1.90% | -16.7% |
| Q1 2018 | $46,086,000 | -3.9% | 2,352,525 | -0.6% | 2.28% | -4.7% |
| Q4 2017 | $47,945,000 | +11.9% | 2,366,480 | -4.1% | 2.39% | +11.5% |
| Q3 2017 | $42,846,000 | +32.2% | 2,466,684 | -2.4% | 2.14% | +24.7% |
| Q2 2017 | $32,415,000 | +7.9% | 2,528,462 | +9.1% | 1.72% | +8.3% |
| Q1 2017 | $30,047,000 | +41.8% | 2,318,433 | +8.1% | 1.58% | +23.2% |
| Q4 2016 | $21,188,000 | -21.4% | 2,144,549 | -3.9% | 1.29% | -23.8% |
| Q3 2016 | $26,964,000 | +37.8% | 2,232,114 | -1.6% | 1.69% | +32.6% |
| Q2 2016 | $19,571,000 | +23.0% | 2,267,787 | +35.0% | 1.27% | +18.1% |
| Q1 2016 | $15,911,000 | – | 1,680,169 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |